Clinical Trial Update: Epcoritamab and Rituximab for First-line Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating epcoritamab in combination with rituximab as first-line therapy for follicular lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)
• Rituximab (rituximab)

Snippet

Sponsor: Reid Merryman, MD | Conditions: Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult | Phase 2 | Status: RECRUITING